The Promise of CAR T-Cell Therapy

Chimeric  Antigen T-cell therapy or CAR T-cell therapy is one of the most promising types of immunotherapy.  Early results as well as experiences with approved CAR T-cell therapies have shown the potential to induce sustained remissions in patients with refractory disease. Because the majority of adult B-cell malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non–Hodgkin's lymphoma, remain,...

KATHERINE Trial: Trastuzumab Emtansine Reduces Risk of Invasive Recurrence of Breast Cancer by 50%

Results from the Phase III KATHERINE Clinical Trial (NCT01772472), supported by F. Hoffmann Genentech/Roche and presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in the Henry B. González Convention Center located along the banks of the River Walk in Downtown San Antonio, Texas, shows that substituting (ado-) trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) for adjuvant...

Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma Shows Promise

Initial safety data from an ongoing proof-of-concept trial of JCARH125, an investigational BCMA-targeting CAR T being developed by Juno Therapeutics/Celgene Corporation) in patients with relapsed/refractory multiple myeloma, were  presented by Sham Mailankody, MBBS, in an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA (Abstract #957). The data from 44 patients...

The Future of Medicine is Bright: Personalized Medicine, Predictive Analytics and Big Data

Modern medicine is to change dramatically. Over the past 200 years medicine has seen extraordinary developments and advances. From microbiology to the sequencing of the human genome, the advent of CRISPR–Cas genome editing to potentially treat disease and advance drug discovery and development, as well as a better understanding of underlying biology of cancer and hematological disease, and the availability...

Optimal Pain Control Hampered by Misconceptions about Opioids

A cross-sectional survey conducted at the Sarawak General Hospital in Malaysia shows that misconceptions about the use of strong opioids undermines optimal pain control among Asian cancer patients undergoing chemotherapy and radiotherapy. Results from survey, presented at the ESMO Asia 2018 Congress held in Singapore, November 23 - 25, 2018, included 133 patients with solid tumors across all stages...

ESMO Launches Partnership Designed to Promote Asian-European Collaboration In Rare Cancers Research

Rare cancers inherently make it difficult to collect data, build clinical expertise and treat affected patients. The challenges to find cures for these cancers are best addressed by international collaboration. To promote the collaboration between European and Asian cancer researchers, the European Society for Medical Oncology (ESMO) has launched multi-stakeholder partnership called Rare Cancers Asia (RCA).  The partnership is expected...

Australian Kazia Therapeutics Presents ‘Trial in Progress’ Data for Glioblastoma Study

Results for GDC-0084, an investigational drug being being developed by Australian- based and oncology-focused Kazia Therapeutics, were presented during the annual meeting of the Society for Neuro-Oncology (SNO), held in in New Orleans, LA November 16 - 18, 2018. The investigational agent is currently in human trials for the treatment of patients with glioblastoma, the most common and most aggressive...

Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results

Preliminary results from the CAPTIVE / KEYNOTE-192 study (NCT02798406) dose escalation study evaluating a single intratumoral injection of DNX-2401 (tasadenoturev; DNAtrix) followed by standard dosing with pembrolizumab (Keytruda®; Merck Sharp & Dohme Corp/MSD) every three weeks to determine the optimal dose, safety, and efficacy in patients with recurrent glioblastoma, demonstrate that combination of the two agents is well tolerated...

Lower Burden and Better Mental Health Outcomes Reported by African-American Caregivers

Informal caregivers, such as partners, children and other family members as well as close friends, provide essential support to cancer patients. Following diagnosis and the first phases of the disease, these individuals may offer practical help by accompanying the patient during doctor visits, care and, provide psychological support to help the 'new' patient cope with uncertainty and fear. In...

Cancer Mortality May Increase for Successive Generations of Latino Immigrants

In 2016 the United States Census Bureau estimated that 18% of the population in the continental United States and Hawaii, approximately 57.5 million people, identified themselves as Hispanic or Latino. Although cancer is the leading cause of death among Latinos, accounting for 21% of deaths, they are generally less likely than non-Hispanic whites to be diagnosed with the most common...

right side

ads

Related articles